Thirumalai Chemicals reported a standalone net profit of ₹142 crore for the quarter ended June 30, 2026 (Q1FY27), marking a significant turnaround from the net loss of ₹138 crore recorded in Q1FY26. This recovery was driven by improved gross margins, which expanded to 35% from 16% year-on-year, supported by better business margins in Phthalic Anhydride (PAn) and cost-saving initiatives. In contrast, the consolidated entity recorded a net loss of ₹437 crore, primarily due to operational losses from its overseas subsidiary, TCL Specialties LLC, and higher finance costs associated with the ongoing construction of its manufacturing plant in the USA. The Group aims to commence the first phase of commercial operations at the new US facility by December 2026.

Financial Performance Overview

Standalone revenue from operations declined to ₹331 crore in Q1FY27 from ₹446 crore in the previous year’s quarter. Despite lower revenue, the standalone entity achieved an EBITDA of ₹51 crore, up significantly from ₹7 crore in Q1FY26. Gross profit rose to ₹118 crore from ₹71 crore, reflecting a margin expansion driven by market factors and small-scale cost-saving projects. Finance costs on a standalone basis increased to ₹24 crore from ₹16 crore. Basic and diluted earnings per share (EPS) stood at ₹1.2, recovering from a loss per share of ₹1.4 in Q1FY26.

The following table highlights key financial metrics:

Consolidated revenue rose to ₹547 crore from ₹450 crore in Q1FY26. However, consolidated finance costs surged to ₹52 crore from ₹18 crore, reflecting the capital expenditure burden associated with the US subsidiary’s manufacturing plant construction. The consolidated loss per share improved slightly to ₹3.6 from ₹5.9 in the prior year.

Liquidity and Fund Raising Strategy

The Group faces significant working capital challenges, with current liabilities exceeding current assets by ₹7,421 crore as of June 30, 2026. This gap is largely attributable to capital expenditure incurred by TCL Specialties LLC. The subsidiary is engaging with prospective lenders to raise debt funding of up to USD 130 to 180 million to support project completion and refinance existing borrowings. Financing is expected to be completed by October 2026.

At the standalone level, current liabilities exceed current assets by ₹3,253 crore, excluding loans receivable from subsidiaries amounting to ₹4,566 crore. The Board approved raising up to ₹750 crore through instruments including qualified institutions placement (QIP), preferential issue, further public offer, rights issue, or any permissible combination, subject to shareholder and regulatory approvals.

Operational Updates and Market Context

The PAn business performance was impacted by raw material shortages, particularly at the Dahej plant where working capital constraints affected procurement. However, the PAn reactor achieved 95% capacity utilization. The DGTR’s May 2026 sunset review recommended extending anti-dumping duties on Chinese and Korean imports for a further five years, providing some protection against structural pressure from Chinese overcapacity. Additionally, the India–EU Free Trade Agreement concluded in January 2026 will open zero-duty chemical access once implemented from 2027.

At Optimistic Organic Specialities Bhd (OOSB), Malaysia, focused operational optimization and cost-control measures supported a significant earnings improvement, resulting in positive EBITDA. The Board also approved the sale of four windmills with an installed capacity of 3.2 MW to TN Oxygen Private Limited for ₹10.35 crore to strengthen short-term liquidity.

What the Numbers Show

The divergence between standalone profitability and consolidated losses highlights the transitional phase of Thirumalai Chemicals’ global expansion strategy. While the core Indian operations are demonstrating robust margin recovery and operational efficiency—evidenced by the jump in standalone EBITDA margin from 2% to 15%—the consolidated bottom line remains weighed down by the capital-intensive US project. The significant rise in consolidated finance costs to ₹52 crore underscores the funding pressure during this construction phase. The upcoming commencement of commercial operations in December 2026 is critical for converting this capex burden into revenue-generating assets, potentially leveraging cost arbitrage between India and the US.

Thirumalai Chemicals received a show cause notice on July 30, 2026, from the Office of Deputy Commissioner, Commercial Tax Department, Ranipet, Tamil Nadu, demanding Rs. 2292.66 lakhs in tax and other dues. The notice, issued under Section 73 of the CGST Act 2017, cites alleged output turnover discrepancies and input tax discrepancies for the period 2022-23. This regulatory action requires the company to address claims that could impact its financial position, though management asserts the final implication will be minimal.

The disclosure was made to the National Stock Exchange of India Limited and BSE Limited on July 31, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also references SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Aditya Sharma, Company Secretary & Compliance Officer, signed the disclosure, confirming the company’s intent to submit a response to the authority within the prescribed timelines.

The demand order, issued under DRC01, breaks down the total liability into tax, interest, and penalty components. The primary contention involves alleged discrepancies in output turnover and input tax credits claimed during FY 2022-23. The Commercial Tax Department, Ranipet, has quantified the potential dues based on these alleged violations.

The company maintains that the demands are erroneous and not sustainable. Management firmly believes that the financial implication, if any, arising from this notice is likely to be very insignificant and will not have a material impact on the financial position of Thirumalai Chemicals. The firm is preparing its defense against the allegations of input tax and output turnover mismatches.

Regulatory Context

The notice falls under Section 73 of the CGST Act 2017, which typically applies to cases involving non-payment or short-payment of tax due to honest mistakes or misunderstandings, as opposed to fraud or wilful misstatement. The company’s compliance team, led by Company Secretary Aditya Sharma, has ensured timely disclosure to stock exchanges as mandated by SEBI regulations. The next step involves the submission of a detailed response to the Deputy Commissioner, addressing each point raised in the DRC01 notice.

What the Numbers Show

The structure of the demand reveals that the base tax liability constitutes approximately 59% of the total notice amount, with interest accounting for roughly 35%. The penalty component is relatively smaller at about 6% of the total. This breakdown suggests that the core dispute lies in the calculation of taxable turnover and eligible input tax credits rather than punitive measures for intentional evasion. If the company’s defense holds, the entire Rs. 2292.66 lakh figure may be reduced significantly or nullified, aligning with management’s assertion of an insignificant financial impact.